Synopsis: Anuh Pharma Ltd. reported a stable Q4 FY26 performance with revenue rising to Rs. 202 crore, supported by steady demand across pharmaceutical products and export markets. The company maintained consistent profitability despite margin pressure and announced a final dividend of Rs. 1.50 per share for FY26.
Anuh Pharma a prominent manufacturer of active pharmaceutical ingredients (APIs), delivered a steady operational performance in Q4 FY26. The company reported stable revenue growth and maintained profitability despite rising operational costs during the quarter. Backed by healthy export demand and strong industry tailwinds, Anuh Pharma also announced a final dividend for shareholders, reflecting confidence in its overall business fundamentals.
Anuh Pharma Ltd. currently has a market capitalization of Rs. 782 crore, with the stock trading near Rs. 78 down by 4.50% compared to its previous close of Rs. 81. The stock touched a 52-week high of Rs. 114.9 and a low of Rs. 67. The company trades at a P/E ratio of 19.1, while its ROCE and ROE stand at 15.9 percent and 12.1 percent respectively, reflecting stable profitability and operational efficiency.
Anuh Pharma reported revenue of Rs. 202 crore in Q4 FY26, registering a marginal sequential growth of 2.54 percent compared to Rs. 197 crore reported in Q3 FY26. On a year-on-year basis, revenue increased by 2.02 percent from Rs. 198 crore reported in Q4 FY25, supported by steady demand across key pharmaceutical products and export markets.
The company’s operating profit stood at Rs. 20 crore in Q4 FY26, compared to Rs. 19 crore in Q3 FY26 and Q4 FY25, reflecting stable operational performance. Operating profit margin remained steady at 10 percent during the quarter.
Profit before tax came in at Rs. 16 crore in Q4 FY26, declining by 11.11 percent sequentially from Rs. 18 crore reported in Q3 FY26. On a YoY basis as well, profit before tax slipped by 5.88 percent from Rs. 17 crore reported in Q4 FY25, mainly due to higher operational expenses and lower other income.
Net profit stood at Rs. 12 crore during Q4 FY26, compared to Rs. 13 crore in Q3 FY26 and Rs. 12 crore in Q4 FY25. While profitability remained stable on a yearly basis, sequential earnings witnessed slight pressure due to rising expenses and softer margins.
The board of Anuh Pharma recommended a final dividend of Rs. 1.50 per equity share having a face value of Rs. 5 each for FY26. The dividend represents a 30 percent payout and is subject to shareholder approval at the upcoming Annual General Meeting.
Industry Outlook
India’s pharmaceutical industry continues to witness strong long-term growth supported by rising healthcare spending, increasing exports, government incentives, and expanding global demand for generic medicines and APIs. According to Bain & Company, the Indian pharmaceutical market is expected to grow to Rs. 10,28,280–11,13,970 crore by 2030.
The government’s Production Linked Incentive (PLI) scheme, increased budget allocation to the pharmaceutical sector, and focus on reducing import dependency are expected to strengthen domestic manufacturing. India also remains one of the world’s largest suppliers of generic medicines with over 2,000 WHO-GMP approved facilities and strong export capabilities across global markets.
Anuh Pharma delivered a stable Q4 FY26 performance with steady revenue growth and consistent profitability despite margin pressures during the quarter. The company’s strong presence in the API segment, healthy balance sheet, and regular dividend payout continue to support investor confidence. With favorable industry trends and rising global demand for pharmaceutical products, the company remains well-positioned for long-term growth.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Anuh Pharma Shares Slip 4.5% Post Steady Q4 FY26 Performance; Declares 30% Dividend appeared first on Trade Brains.